Join
Live feed
·
PRReleasevia Quantisnow
Organon & Co. logo

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
OGN· Organon & Co.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OGN (Organon & Co.) and more on Quantisnow.